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Take-home message
Our study showed for the first time that non-allergic asthma patients have worse asthma control 
and lung function in association with lower FeNO. 






























































Allergic asthma is characterised by the presence of circulating specific immunoglobulin E (IgE) 
or positive skin prick test (SPT) to common aeroallergen. Type-2 inflammatory (T2) cytokines 
stimulates IgE synthesis in response to aeroallergen, resulting in chronic eosinophilic (Eos) airway 
mucosal inflammation. 
Non-allergic asthma is defined by a negative SPT and is more typically of later onset with female 
predominance [1]. While the inflammation in allergic asthma is driven by external allergen, there 
is no identifiable allergen in non-allergic asthma where the mechanisms of airway inflammation 
remains unclear. 
To our knowledge, presently there are no studies looking at  T2 biomarkers as  fractional exhaled 
nitric oxide (FeNO) and Eos, or small airway function as impulse oscillometry (IOS), comparing 
between allergic and non-allergic asthma. IOS has been utilised to identify small airway 
dysfunction (SAD) defined by raised peripheral airway resistance which is the difference between 
resistance at 5 Hz and 20 Hz (R5-R20) and the area under the reactance curve (AX) which reflects 
the peripheral lung compliance. Indeed the SAD phenotype is  related to worse asthma control [2].
We therefore wished to see if there were differences in asthma control (as ACQ), lung function (as 
spirometry and IOS) and T2 biomarkers (as FeNO and blood Eos) in relation to allergic status in 
patients with persistent asthma. Retrospectively, we evaluated a cohort of 56 serial patients with 
persistent asthma who attended our research unit for screening into clinical trials. All asthmatic 
subjects included were receiving inhaled corticosteroids (ICS) at the time of the visit. Allergy was 
defined as positive SPT to at least one common aeroallergen. IOS (Jaeger Masterscreen, Hochberg, 
Germany) and spirometry (Micromedical, Chatham, United Kingdom) were performed in 
triplicate according to European Respiratory Society guidelines. Caldicott guardian approval was 
obtained to allow access to the patient identifiable National Health Service data on blood Eos, and 
all patients consented for their screening data to be accessed.
We analysed the values for asthma control questionnaire (ACQ-6), forced expiratory volume in 1 
second (FEV1), forced vital capacity (FVC), forced expiratory flow at 25-75% of FVC  (FEF25-
75), IOS (R5, R5-R20, AX), FeNO and Eos. Comparisons for each outcome were made by 





























































unpaired Student’s t test using Bonferonni corrections to avoid confounding the overall alpha error 
which was set at 0.05 (2-tailed). 
Overall mean age was 51 years, 33 females, mean FEV1 2.65L, mean ACQ score of 1.5, and mean 
ICS dose (beclomethasone equivalent) of 700ug. 28 subjects were identified with either allergic or 
non-allergic asthma. Median number of positive SPT in allergic asthma was 2 (interquartile range 
2-4) aeroallergens in the allergic group and none in the non-allergic group. 
The characteristics of the study subjects and significant comparisons are summarised in Table 1. 
Patients with allergy had a lower body mass index (BMI) (P=0.01) and were younger (P=0.005). 
In allergic asthma, the FeNO was significantly higher than in non-allergic asthma, while after 
Bonferroni correction there was a non-significant numerical difference in Eos amounting to 130 
cells/ul. In terms of lung function tests, spirometry for FEV1 and FVC in litres but not FEF25-75   
and all IOS measurements were significantly worse comparing non allergic to allergic asthma. 
FEV1 and FVC as % predicted were not significant with mean values of 91% vs 90% (P=0.72) 
and 106% vs 103% (P=0.45) comparing allergic and non-allergic asthma respectively. ACQ was 
also significantly worse in non-allergic asthma.
Our results showed that ACQ, which is a strong predictor of future exacerbations [3], was worse 
in the non-allergic group with mean difference exceeding minimal clinically important difference 
(MCID) of 0.5 [4]. Furthermore, the mean difference in FEV1 also exceeded the MCID of 230ml 
[5]. 
As expected, the FeNO and Eos levels in allergic asthma were higher reflecting the underlying 
type 2 inflammatory cytokines. One might perhaps expect lung function to be worse in the presence 
of high T2 biomarkers in conjunction with the underlying allergic burden. In converse, our results 
demonstrated that lung function including the small airways outcomes on IOS were indeed worse 
in non-allergic asthma. This finding is also consistent with a previous study by Ulrik et al [6] 
showing that the rate of decline in FEV1 was greater in patients with allergic  asthma than in non-
allergic asthma. 
As the mean ICS dose in the non-allergic group was approximately 100µg higher than the allergic 
group, albeit non-significant, we might therefore have expected the allergic group to exhibit poorer 
outcomes in terms of ACQ or lung function, whereas the opposite was observed. This can be 





























































explained by T2 high asthma being generally more responsive to ICS therapy [7]. For example, 
Price et al [8] showed that high T2 biomarkers such as FeNO predicts a better ACQ response to 
ICS, although this study did not differentiate with regards to allergic status. It has also been shown 
that allergic patients who have high FeNO and blood eosinophils exhibit greater reductions in 
exacerbations in response to omazilumab [9]. 
We duly recognise that there were limitations to our study. First our data was retrospective and 
cross-sectional. Being a cross sectional study we have no measure of inhaler adherence comparing 
the two groups of patients, which might perhaps account for differences in control. Also we may 
have been subject to selection bias, given that these were patients who self-selected for inclusion 
into clinical trials and hence may not be representative of the wider population of asthma patients 
per se. Our sample size was rather small, although the significant differences we observed in lung 
function and symptoms were similar to a previous study [6]. 
In summary, we have shown that non allergic asthma patients have worse asthma control and lung 
function in association with lower FeNO. Such patients may be more difficult to manage in terms 
of not having treatable traits directed at allergy, FeNO and eosinophils. Our data emphasises the 
importance of detailed phenotyping in asthma patients in order to properly characterise allergic 
status, T2 biomarkers and lung function. 
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Age 45 (17) 57 (13) -
                 F/M 15/13 18/10 -
BMI 28 (5) 32 (7) -
ICS (µg) 644 (300) 754 (390) -
ICS + LABA 64% 68% -
LAMA 18% 21% -
LTRA 36% 29% -
THEO 4% 7% -
OAH 29% 0% -
INS 57% 0% -
ACQ 1.13 (0.86) 1.80 (0.98) 0.009
FEV1 (L) 2.92 (0.79) 2.37 (0.67) 0.021
FVC (L) 4.02 (0.77) 3.30 (0.79) 0.003
FEF25-75 (L/s) 2.35 (0.11) 1.71 (0.87) 0.060
AX (kPa/L) 0.73 (0.58) 1.46 (1.17) 0.015
R5  (kPa/L.s) 0.42 (0.11) 0.56 (0.17) 0.003
R5-R20  (kPa/L.s) 0.07 (0.06) 0.14 (0.10) 0.009
FeNO (ppb) 55 (28) 37 (28) 0.036
Eos (cells/µL) 413 (198) 283 (251) 0.074
BMI = body mass index, ICS as beclomethasone equivalent dose, LABA = long acting β2 
agonist, LAMA = long acting muscarinic antagonist, LTRA = leukotriene receptor 
antagonist, THEO = theophylline, OAH = oral antihistamine, INS = intranasal steroid. AX= 
area under the reactance curve, R5=resistance at 5 Hz, R5-R20=difference between 
resistance at 5Hz and 20Hz. Values are presented as mean and standard deviation (SD).
P values are shown as Bonferroni corrected.
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